Fulvestrant-induced toxic epidermal necrolysis

Detalhes bibliográficos
Autor(a) principal: Morales-Conde,Macarena
Data de Publicação: 2019
Outros Autores: López-Ibáñez,Natividad, Calvete-Candenas,Julio, Mendonça,Francisco Manuel Ildefonso
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Anais brasileiros de dermatologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000200218
Resumo: Abstract Toxic epidermal necrolysis is a condition with massive keratinocyte apoptosis, and it is associated with high mortality rates. Fulvestrant, an estrogen receptor antagonist, is indicated in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. To our knowledge, this is the first described case of toxic epidermal necrolysis due to fulvestrant. A 56-year-old woman received 500 mg of intramuscular fulvestrant monthly for metastatic ductal carcinoma of the breast. Five days after the first dose, the patient presented with a maculopapular rash that evolved to blisters, and a detachment of the epidermis in over 30% of the total body surface area. Histological analysis was compatible with toxic epidermal necrolysis. Fulvestrant was discontinued, topical management and supportive care were initiated.
id SBD-1_310e65c742f2243daaed8b091f875db1
oai_identifier_str oai:scielo:S0365-05962019000200218
network_acronym_str SBD-1
network_name_str Anais brasileiros de dermatologia (Online)
repository_id_str
spelling Fulvestrant-induced toxic epidermal necrolysisBreast neoplasmsChemotherapy, adjuvantDrug-related side effects and adverse reactionsDrug therapyStevens-Johnson syndromeAbstract Toxic epidermal necrolysis is a condition with massive keratinocyte apoptosis, and it is associated with high mortality rates. Fulvestrant, an estrogen receptor antagonist, is indicated in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. To our knowledge, this is the first described case of toxic epidermal necrolysis due to fulvestrant. A 56-year-old woman received 500 mg of intramuscular fulvestrant monthly for metastatic ductal carcinoma of the breast. Five days after the first dose, the patient presented with a maculopapular rash that evolved to blisters, and a detachment of the epidermis in over 30% of the total body surface area. Histological analysis was compatible with toxic epidermal necrolysis. Fulvestrant was discontinued, topical management and supportive care were initiated.Sociedade Brasileira de Dermatologia2019-04-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000200218Anais Brasileiros de Dermatologia v.94 n.2 2019reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1590/abd1806-4841.20197964info:eu-repo/semantics/openAccessMorales-Conde,MacarenaLópez-Ibáñez,NatividadCalvete-Candenas,JulioMendonça,Francisco Manuel Ildefonsoeng2019-05-13T00:00:00Zoai:scielo:S0365-05962019000200218Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2019-05-13T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false
dc.title.none.fl_str_mv Fulvestrant-induced toxic epidermal necrolysis
title Fulvestrant-induced toxic epidermal necrolysis
spellingShingle Fulvestrant-induced toxic epidermal necrolysis
Morales-Conde,Macarena
Breast neoplasms
Chemotherapy, adjuvant
Drug-related side effects and adverse reactions
Drug therapy
Stevens-Johnson syndrome
title_short Fulvestrant-induced toxic epidermal necrolysis
title_full Fulvestrant-induced toxic epidermal necrolysis
title_fullStr Fulvestrant-induced toxic epidermal necrolysis
title_full_unstemmed Fulvestrant-induced toxic epidermal necrolysis
title_sort Fulvestrant-induced toxic epidermal necrolysis
author Morales-Conde,Macarena
author_facet Morales-Conde,Macarena
López-Ibáñez,Natividad
Calvete-Candenas,Julio
Mendonça,Francisco Manuel Ildefonso
author_role author
author2 López-Ibáñez,Natividad
Calvete-Candenas,Julio
Mendonça,Francisco Manuel Ildefonso
author2_role author
author
author
dc.contributor.author.fl_str_mv Morales-Conde,Macarena
López-Ibáñez,Natividad
Calvete-Candenas,Julio
Mendonça,Francisco Manuel Ildefonso
dc.subject.por.fl_str_mv Breast neoplasms
Chemotherapy, adjuvant
Drug-related side effects and adverse reactions
Drug therapy
Stevens-Johnson syndrome
topic Breast neoplasms
Chemotherapy, adjuvant
Drug-related side effects and adverse reactions
Drug therapy
Stevens-Johnson syndrome
description Abstract Toxic epidermal necrolysis is a condition with massive keratinocyte apoptosis, and it is associated with high mortality rates. Fulvestrant, an estrogen receptor antagonist, is indicated in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. To our knowledge, this is the first described case of toxic epidermal necrolysis due to fulvestrant. A 56-year-old woman received 500 mg of intramuscular fulvestrant monthly for metastatic ductal carcinoma of the breast. Five days after the first dose, the patient presented with a maculopapular rash that evolved to blisters, and a detachment of the epidermis in over 30% of the total body surface area. Histological analysis was compatible with toxic epidermal necrolysis. Fulvestrant was discontinued, topical management and supportive care were initiated.
publishDate 2019
dc.date.none.fl_str_mv 2019-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000200218
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000200218
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/abd1806-4841.20197964
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
dc.source.none.fl_str_mv Anais Brasileiros de Dermatologia v.94 n.2 2019
reponame:Anais brasileiros de dermatologia (Online)
instname:Sociedade Brasileira de Dermatologia (SBD)
instacron:SBD
instname_str Sociedade Brasileira de Dermatologia (SBD)
instacron_str SBD
institution SBD
reponame_str Anais brasileiros de dermatologia (Online)
collection Anais brasileiros de dermatologia (Online)
repository.name.fl_str_mv Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)
repository.mail.fl_str_mv abd@sbd.org.br||revista@sbd.org.br
_version_ 1752126423377641472

Registros relacionados